AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new gastroesophageal cancer trial, DECIPHER, that will ...
DeCipher leverages advanced AI models, ChatGPT3.5 and 4, specifically optimized for analyzing smart contracts. The resulting "smart contract-specialized GPT" is an incredibly precise tool that has ...
Decipher test scores are independently associated with biopsy upgrades in men on active surveillance for Gleason grade group 1 prostate cancer. Higher Decipher scores on the initial test are ...
GenomeDx Biosciences announced data from two studies showing that Decipher Prostate Cancer Classifier significantly altered treatment decisions and increased confidence in treatment decision-making ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...
Bunzz PTE LTD, a Singapore-based tech company, is thrilled to announce the successful release of “DeCipher“, a revolutionary AI-powered tool designed to transform the process of generating smart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results